Patents by Inventor David Burkhardt

David Burkhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250104806
    Abstract: The present disclosure relates to an improved method for analyzing sequencing data to detect cross-sample contamination in a test sample. Determining cross-contamination in a test sample can be informative for determining that the test sample will be less likely to correctly identify the presence of cancer in the subject. Pre-determined single nucleotide polymorphisms selected from: an allele present in a select database or a genotyping SNP associated with a sample type are used to identify. A sample is determined to be contaminated using the determined contamination probabilities of the one or more pre-determined SNPs.
    Type: Application
    Filed: January 27, 2023
    Publication date: March 27, 2025
    Inventors: Ruth Mauntz, Siddhartha Bagaria, David Burkhardt, Matthew H. Larson, Monica Portela dos Santos Pimentel
  • Publication number: 20230086722
    Abstract: Methods for measuring subpopulations of target molecules (e.g., polypeptides and/or cell-free ribonucleic acid) are provided. In some embodiments, methods of generating a sequencing library from a plurality of RNA molecules in a test sample obtained from a subject are provided, as well as methods for analyzing the sequencing library to detect, e.g., the presence or absence of a disease.
    Type: Application
    Filed: September 9, 2022
    Publication date: March 23, 2023
    Inventors: Matthew LARSON, Ruth E. MAUNTZ, David BURKHARDT
  • Publication number: 20220301654
    Abstract: Methods and systems for determining a subject's likelihood of responding to a treatment by assessing the subject's cell-free DNA (cfDNA) sample include receiving sequence data gathered from sequencing the cfDNA sample, generating a feature matrix of values that correspond to synonymous and nonsynonymous mutations detected in the sequence data, and predicting, based on analysis of the feature matrix at a TMB prediction model, a tumor mutational burden (TMB) for a tissue of interest at the subject. The predicted TMB is evaluated to determine whether a set of criteria indicating a likely response to treatment is met. The set of criteria can include criterion(s) that are met when the predicted TMB is high, when the predicted TMB corresponds to a predicted tumoral heterogeneity indicative of homogeneous tissue, when the predicted TMB corresponds to a tumor fraction indicative of a positive responder, or any combination thereof.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 22, 2022
    Inventors: Jing XIANG, Anton VALOUEV, David BURKHARDT, Nathan HUNKAPILLER, Eric FUNG, Xiaoji CHEN, Byoungsok JUNG
  • Publication number: 20210388451
    Abstract: Methods for measuring subpopulations of cell-free ribonucleic acid (RNA) molecules are provided. In some embodiments, methods of generating a sequencing library from a plurality of RNA molecules in a test sample obtained from a subject are provided, as well as methods for analyzing the sequencing library to detect, e.g., the presence or absence of a disease.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 16, 2021
    Inventors: Ruth E. MAUNTZ, Matthew LARSON, Archana SHENOY, Arash JAMSHIDI, David BURKHARDT
  • Publication number: 20210065847
    Abstract: Systems and methods for determining consensus base calls in nucleic acid sequencing are provided. A sequencing dataset is obtained corresponding to a plurality of base reads for a first base position within a plurality of base positions of a target nucleic acid molecule. The sequencing dataset includes at least two features, for each base read of the plurality of base reads. The at least two features are selected from among the features: a nucleotide base, a read quality score, a strand identifier, a trinucleotide context of the base read, and a confidence score associated with the trinucleotide context. The sequencing dataset is transformed into a feature tensor representing a distribution of the plurality of features in the sequencing dataset. The feature tensor is assessed with a classifier to determine a consensus base call for the first base position. The consensus base call comprises a predicted nucleotide base.
    Type: Application
    Filed: August 28, 2020
    Publication date: March 4, 2021
    Inventors: Anton Valouev, Shirley Chen, David Burkhardt, Christopher Chang